Home

Paige and Oncoclínicas Strengthen Leadership in AI-Driven Cancer Diagnostics Across Brazil

via Business Wire

Oncoclínicas&Co Utilizes Paige’s AI-Assisted Diagnostic Applications to Enhance Diagnostic Capabilities and Further Support Patient Safety

Paige, a leader in next-generation AI technology, announced the continued and expanded use of its innovative AI-assisted diagnostic applications by long-time customer, Oncoclínicas&Co (Oncoclínicas), the largest private group of cancer care in Latin America. With a commitment to enhancing diagnostic capabilities and improving patient safety, Oncoclínicas has utilized Paige’s technology across prostate and breast cancer diagnosis, supporting its commitment to advancing pathology standards throughout Brazil.

Oncoclínicas employs a rigorous approach where all digitized prostate and breast cancer biopsy whole-slide images are analyzed by pathologists using AI as an adjunct diagnostic tool. This process provides extra layers of patient safety, enhancing both sensitivity and efficiency for the pathologists using the technology. Since August 2021, Oncoclínicas has utilized AI to support the review of over 23,000 prostate and breast biopsies.

These results demonstrate the scale and commitment of Oncoclínicas to AI integration in their diagnostic workflow, which has led to Oncoclínicas’ achieving:

  • Faster second reader sign-out for senior pathologists using FullFocus™ and AI support.1
  • Enhanced detection rates, including the identification of approximately .5% of precursor non-obligatory breast lesions that were not initially detected by pathologists.1
  • Improved diagnostic consistency and efficiency through the use of Paige Prostate and Paige Breast AI Suites.1

Dr. Leonard Medeiros da Silva, pathologist at OC Medicina de Precisão, an integrated laboratory of Oncoclínicas&Co dedicated to pathological anatomy, genetic testing and Big Data, reports a positive experience with Paige Prostate. "It aligns with Oncoclínicas published data showing nearly 100% sensitivity and 93% specificity,” he notes. “The specialist also commends the technology's effectiveness in both cancer detection and accurate Gleason score determination.”

“We are proud to support Oncoclínicas in their mission to offer cutting-edge cancer diagnostic solutions,” said Dr. Juan Retamero, Medical Vice President at Paige. “Their success in implementing AI technology is a testament to their dedication to clinical excellence and their forward-thinking approach to pathology. Our long-term partnership underscores Paige’s commitment to providing access to high-quality AI technology globally, helping pathologists provide better diagnoses for their patients.”

“Over the past few months, I’ve had the opportunity to witness how the integration of digital pathology, biomarkers, AI, and genomics is accelerating the advancement of precision medicine, and, more importantly, improving patients’ quality of life and offering new hope in the fight against cancer,” said Rodrigo Alvarenga, Operations Executive at Oncoclínicas&Co. “At both the 2025 USCAP in Boston and ASCO in Chicago, it became clear that precision medicine is no longer a distant goal, but a present-day reality that can expand access to advanced technologies and enable more cost-effective care. We’ve reached an exciting point of no return, the convergence of AI, pathology, and genomics is not only transforming cancer care but is also critical to the long-term sustainability of our healthcare systems.”

In Brazil, FullFocus™ and all AI assisted diagnostic applications such as the Paige Prostate Suite and the Paige Breast Suite are for Research Use Only. Not for use in diagnostic procedures.

1Figures are based on independent clinical research conducted by Oncoclínicas&Co. Finding an average of 12,000 breast biopsies and surgical specimens were analyzed in 2024. The Paige Breast Suite as a second reader detected 55 non-obligatory precursor breast lesions that were not initially detected by pathologists. Additionally, after utilizing FullFocus™ with the Paige Prostate Suite, the average time to read a slide and complete a report reduced to one minute and 10 seconds.

About Oncoclínicas&Co

Oncoclínicas&Co is the largest group dedicated to cancer treatment in Latin America, with a highly specialized and innovative model focused on the oncology journey. With a medical staff of over 2,900 oncology specialists, the company operates in 40 Brazilian cities, totaling more than 140 units. Focused on research, technology, and innovation, the group has conducted approximately 682,000 treatments in the past 12 months. Oncoclínicas follows international standards of excellence, integrating outpatient clinics with high-complexity cancer centers, enhancing treatment through precision medicine and genomics. As the exclusive partner of the Dana-Farber Cancer Institute in Brazil, affiliated with Harvard Medical School, it has acquired Boston Lighthouse Innovation (USA) and holds a stake in MedSir (Spain). It is also part of the IDIVERSA index of B3, reinforcing its commitment to diversity. With the goal of expanding its global mission to overcome cancer, Oncoclínicas has entered Saudi Arabia through a joint venture with the Al Faisaliah Group, bringing its oncology expertise to a new continent. Learn more at: www.grupooncoclinicas.com.

About Paige

Paige is pushing the boundaries of AI to solve cancer’s most critical issues, revolutionizing cancer care with next-generation technology. By leveraging exclusive access to millions of digitized pathology slides, clinical reports, and genomic data, Paige gains a holistic understanding of cancer, encompassing diverse factors such as gender, race, ethnicity, and geographical regions. This comprehensive data enables Paige to create advanced AI solutions that redefine cancer detection, diagnosis, and treatment. With a unique, intricate understanding of tissue, Paige sets new standards in precision diagnostics, earning the distinction of being the first FDA-cleared AI application in pathology. Paige has also developed the first million-slide foundation model for cancer, continuing to lead the way in uncovering novel insights and transforming them into life-changing products. For more information, visit www.paige.ai.

Contacts